Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan

Clinical Nuclear Medicine

Volumn 36, Issue 2, 2011, Pages 109-112

  Giovanella, Luca ^a   Suriano, Sergio ^a   Ceriani, Luca ^a   Verburg, Frederik Anton ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

differentiated thyroid cancer; immunoassay; radioiodine; thyroglobulin; whole body scan

Indexed keywords

HETEROPHILE ANTIBODY; IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; FEMALE; HUMAN; IMMUNOASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; TUMOR DIFFERENTIATION; WHOLE BODY SCANNER;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CELL DIFFERENTIATION; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOASSAY; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 79551587912     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318203bb84     Document Type: Article

References (24)

1. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur JEndocrinol. 2006;154:787-803.
2. Grünwald F, Menzel C, Fimmers R, et al. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med. 1996;37:1962-1964.
3. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carci-noma. J Clin Endocrinol Metab. 2005;90:1440-1445.
4. Giovanella L, Ceriani L, Ghelfo A, et al. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med. 2005;43:843-847.
5. Phan HTT, Jager PL, van der Wall JE, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol. 2008;158:77-83.
6. Park EK, Chung JK, Lim HH, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging. 2009;36:172-179.
7. Giovanella L. High-sensitive thyroglobulin measurements in differentiated thyroid carcinoma management Clin Chem Lab Med. 2008;46:1067-1073.
8. Spencer CA, Bergoglio LM, Kazarosyan M, et al. Clinical impact of thyro-globulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:5566-5575.
9. Giovanella L, Keller F, Ceriani L, et al. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differenti-ated thyroid carcinoma. Clin Chem Lab Med. 2009;47:952-954.
10. Hufner M, Pfahl H, Bethauser H, et al. Comparative plasma thyroglobulin measurements with three non-cross-reactive monoclonal antibodies in meta-static thyroid cancer patients. Acta Endocrinologica. 1998;118:528-532.
11. Schulz R, Bethauser H, Stempka L, et al. Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men. Eur J Clin Invest. 1989;19:459-463.
12. Gospodarowicz M, Wittekind CL, Sobin LH, eds. TNM Classification of Malignant Tumors. 7th ed. New York, NY: John Wiley & Sons 2010.
13. Smallridge RC, Meek S, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab. 2007;92:82-87.
14. Giovanella L, Ceriani L, Ghelfo A. Redefining functional sensitivity of thyroglobulin assay on Immulite platform: implications in thyroid cancer management. Clin Chem Lab Med. 2007;45:1523-1524.
15. Pacini F, Molinaro E, Lippi F, et al. Prediction of disease status by recom-binant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5686-5690.
16. Brendel AJ, Lambert B, Guyot M, et al. Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow up of differen-tiated thyroid carcinoma. Eur J Nucl Med. 1990;16:35-38.
17. Ma C, Kuang A, Xie J, et al. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46:1473-1480.
18. Giovanella L, Ceriani L, Ghelfo A, et al. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol. 2007;67:547-551.
19. Schlumberger M, Hitzel A, Toubert ME, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab. 2007;92:2487-2495.
20. Kohno Y, Tarutani O, Sakata S, et al. Monoclonal antibodies to thyroglobulin elucidate differences in protein structure of thyroglobulin in healthy individ-uals and those with papillary adenocarcinoma. J Clin Endocrinol Metab. 1985;61:343-350.
21. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:123-126.
22. Westbury C, Vini L, Fisher C, et al. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid. 2000;10:171-176.
23. Giovanella L. False-negative thyroglobulin measurement in recurrent/meta-static thyroid carcinomas. Eur J Nucl Med Mol Imaging. 2009;36:326-327.
24. Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.